Riviste scientifiche

Covid-19 news: Health experts say UK contact tracing not robust enough

New Scientist - Lu, 01/06/2020 - 19:40
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic

UK contact tracing plans criticised as lockdown begins to lift

New Scientist - Lu, 01/06/2020 - 18:34
As coronavirus lockdown restrictions are lifted in England, critics say the UK government is moving too quickly and that contact tracing systems designed to slow the spread of the virus aren't yet ready

People who work in offices with more daylight sleep better at night

New Scientist - Lu, 01/06/2020 - 16:32
When employees work in an office with more natural light they perform better in strategic thinking tests and sleep 37 minutes more per night on average

Parkinson’s disease may spread from brain to gut and vice versa

New Scientist - Lu, 01/06/2020 - 09:00
Research in baboons suggests that misfolded proteins linked to Parkinson’s disease can travel from the brain to gut and vice versa – with both routes causing equal amounts of brain cell death

NASA and SpaceX launch astronauts into new era of private spaceflight

New Scientist - Sa, 30/05/2020 - 23:21
On 30 May, SpaceX and NASA pulled off a historic launch – the first private spacecraft to take astronauts into orbit, and the first crewed launch from US soil in 9 years

[Editorial] COVID-19 in Africa: no room for complacency

The Lancet - Sa, 30/05/2020 - 00:00
Despite over 100 000 confirmed cases and infections in every country, the passage of COVID-19 through the African continent remains somewhat enigmatic. High numbers of deaths were expected in the region due to fragile health systems, lack of access to preventive measures, barriers to testing, and potentially vulnerable populations. But, according to WHO, Africa is the least affected region globally, with 1·5% of the world's reported COVID-19 cases and 0·1% of the world's deaths. Although comparisons are inaccurate, mortality rates have been lower compared with outbreaks of similar size elsewhere.

[Comment] Justice and health: The Lancet–Health Equity and Policy Lab Commission

The Lancet - Sa, 30/05/2020 - 00:00
Justice forms the foundation for what we owe each other and what fairness among human beings and institutions involves. Globally, there are large inequalities in health outcomes and opportunities for health. Not only is the global burden of disease distributed unevenly but capabilities to prevent and treat disease are also asymmetrical; those in greatest need often have the least access to human, physical, and financial resources for health. Global health justice provides an account of what justice across our planet embodies, offers solutions to global health problems, and identifies who has responsibilities and what those responsibilities entail for addressing these problems.

[Comment] Offline: After COVID-19—is an “alternate society” possible?

The Lancet - Sa, 30/05/2020 - 00:00
How do we make sense of this pandemic? The first interpretations are now appearing. Slavoj Žižek is a prolific philosopher and cultural theorist. He is the first to produce a volume of reflections—Pandemic! COVID-19 Shakes the World (Polity, 2020). Žižek doubts the epidemic will make us wiser: he insists that “we should resist the temptation to treat the ongoing epidemic as something that has a deeper meaning”. Despite these cautions, we still have an important question to answer: “What is wrong with our system that we were caught unprepared by the catastrophe despite scientists warning us about it for years?” We must accept that “The coronavirus epidemic itself is clearly not just a biological phenomenon which affects humans: to understand its spread, one has to consider human cultural choices…economy and global trade, the thick network of international relations, ideological mechanisms of fear and panic.” Žižek opens his investigation in China—“China thwarts the freedoms of its citizens.” He endorses the view of Li Wenliang, the ophthalmologist who was censored by Wuhan authorities for sharing information about the new SARS-CoV-2 virus and who later died from COVID-19: “There should be more than one voice in a healthy society.” China dealt assertively and successfully with the outbreak in Wuhan.

[World Report] Fears of “highly catastrophic” COVID-19 spread in Yemen

The Lancet - Sa, 30/05/2020 - 00:00
Yemen's health system has been devastated by years of conflict and COVID-19 deaths are reported to be surging in Aden. Sharmila Devi reports.

[World Report] COVID-19 strains remote regions of Peru

The Lancet - Sa, 30/05/2020 - 00:00
The health system in Iquitos is stretched and the true number of COVID-19 cases and deaths is unclear. Barbara Fraser reports from Lima.

[Perspectives] A call for food system change

The Lancet - Sa, 30/05/2020 - 00:00
In shutting down entire societies, the COVID-19 pandemic has exposed the fundamental inequities and inadequacies of market-driven economies that prioritise profits over human welfare. Inequities show up in businesses that furlough employees while paying high salaries and bonuses to executives. They are also revealed by the dependence of food systems on poorly paid workers and cheap global supply chains. The COVID-19 crisis demonstrates how current food systems fail to protect populations from hunger and diet-influenced non-communicable diseases and why the poor, disenfranchised, discriminated against, and chronically ill are those most vulnerable to this disease.

[Correspondence] Time for global health diplomacy

The Lancet - Sa, 30/05/2020 - 00:00
2019 was The Lancet's Year for Nutrition. Highlights included reports from the EAT-Lancet Commission1 and The Global Syndemic Commission,2 both emphasising that global trade systems must be transformed to ensure healthy and sustainable diets. But what developments can be expected following these reports? We might get an indication by considering what has happened since The Lancet's 2009 Trade and Health Series. This Series criticised the trade agreements of the World Trade Organization (WTO) for being detrimental to global health, among other things, by facilitating unhealthy diets.

[Correspondence] Cost-effectiveness of transitional US plans for universal health care

The Lancet - Sa, 30/05/2020 - 00:00
The USA stands alone as the only high-income country not to provide health care as a human right, leaving almost 80 million of its citizens without adequate insurance.1–3 In a 2020 study, we found that securing quality health care for the entire country would save 68 000 lives and 1·73 million life-years annually.4

[Correspondence] Towards more balanced representation in Lancet Commissions

The Lancet - Sa, 30/05/2020 - 00:00
Enthusiastically, Richard Horton1 reports on the foundation of the Italian Institute of Planetary Health at a time when youth strikes, an emerging pandemic of a new coronavirus, and burning forests remind us of our planet being in jeopardy. We agree that something must change so that the undoubtable advances in science and medicine that were made since the time of Lucretius translate into a better life for all humans, no matter who they are, where they were born, and where they live and work.1 Yet, the lamented crisis of trust in science and medicine cannot be overcome by concepts of global health or planetary health unless their actors truly embrace the planetary concept and approaches.

[Correspondence] The health-related determinants of politics

The Lancet - Sa, 30/05/2020 - 00:00
I was pleased to read Richard Horton's Comment about populist politics.1 However, the problem of political populism and solution that he charts out seem somewhat non-sequitur.

[Department of Error] Department of Error

The Lancet - Sa, 30/05/2020 - 00:00
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569–78. In this Article, a sentence has been added to the Acknowledgments as follows: This work was also supported by the China Evergrande Group, Jack Ma Foundation, Sino Biopharmaceutical, Ping An Insurance (Group), and New Sunshine Charity Foundation. In the legend of table 3, “seven-category ordinal scale” has been corrected to “six-category ordinal scale”.

[Department of Error] Department of Error

The Lancet - Sa, 30/05/2020 - 00:00
Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020; 395: 1278–91—In this Article, the second instance of obinutuzumab in the title was misspelled and has been corrected. In table 1, the row labelled Chromosome 17p13·1 deletion or mutated TP53 has been corrected to Chromosome 17p13·1 deletion and/or mutated TP53, and data in this row have been updated.

[Department of Error] Department of Error

The Lancet - Sa, 30/05/2020 - 00:00
Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019; 394: 1940–48—In this Article, the Declaration of interests have been corrected for Karen S McCoy, Bonnie W Ramsey, Steven M Rowe, and John J Welter. These corrections have been made to the online version as of May 28, 2020.

[Department of Error] Department of Error

The Lancet - Sa, 30/05/2020 - 00:00
Gaudinski MR, Coates EE, Novik L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet 2019; 393: 889–98—In figure 2 of this Article, in part C, the group three serum concentration on day 14 should have been 629·32 μg/mL (SD 118·19). This correction has been made to the online version as of May 28, 2020.

[Department of Error] Department of Error

The Lancet - Sa, 30/05/2020 - 00:00
McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020; 395: 1496–505—The appendix of this Article has been corrected as of May 28, 2020.
Condividi contenuti